Ekaterina Malievskaia

Ekaterina Malievskaia is a Russian-born physician whose role in the book’s account of psychedelic therapy is as an advocate and organizer of its effort to enter European health care. Alongside her husband, entrepreneur and health industry consultant George Goldsmith, she devoted energy and resources to winning approval for psilocybin-assisted therapy in the European Union and co-founded Compass Pathways.

Identity and Partnership

The account identifies Malievskaia as a physician born in Russia and Goldsmith’s wife. It presents their partnership as both personal and professional: they worked together to advance the acceptance of psychedelic treatment, with Goldsmith supplying the most detailed public-facing statements about their plans. The text does not provide a separate personal history or describe her medical specialty.

Advocacy for Psychedelic Therapy

At a conference panel on the future of psychedelic psychiatry, Goldsmith appeared as the organizer and moderator, while the discussion brought psychedelic treatment into conversation with senior figures from the mental health establishment. The book places Malievskaia within the effort behind that shift: she and Goldsmith had devoted substantial resources and energy to securing European Union approval for psilocybin-assisted therapy. Their work connects clinical research to the practical question of whether such therapy could become an accepted part of health care.

Compass Pathways and the Treatment Model

Goldsmith formed Compass Pathways with Malievskaia as a co-founder, aiming to build a European program for psilocybin trials and, in time, treatment centers. The initial trials were planned across multiple sites and focused on treatment-resistant depression. Goldsmith envisioned centers in appealing natural settings where patients could receive guided sessions; he also worked with designers at IDEO to rethink the experience of psychedelic therapy. He had raised three million pounds to fund and organize the trials, and former mental-health leaders Paul Summergrad and Tom Insel joined the company’s advisory board. These details establish the scale and institutional ambition of the project, though the book attributes the fundraising, design work, and description of the centers specifically to Goldsmith rather than detailing Malievskaia’s individual responsibilities.

Place in the Book

Malievskaia appears as part of the developing institutional story of psychedelic therapy: not only as a research subject or clinician, but as a physician helping build an organization intended to move treatment toward regulatory and health-system acceptance. The author also names her among the people thanked for enduring lengthy interviews and serving as a teacher during the reporting. Her characterization remains brief, but the repeated placement of her beside Goldsmith makes their partnership a concrete part of the book’s account of how psychedelic therapy might be organized and funded.